QCG
RXRX icon

Quadrant Capital Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Quadrant Capital Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.56K Sell
3,114
-39
-1% -$151 ﹤0.01% 2199
2025
Q4 		$12.9K Buy
+3,153
New +$15.6K ﹤0.01% 2137
2025
Q1 		– Sell
-143
Closed -$967 – 2831
2024
Q4 		$967 Hold
143
– – ﹤0.01% 2593
2024
Q3 		$943 Buy
+143
New +$1.02K ﹤0.01% 2602

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Quadrant Capital Group's RXRX Position: Q1 2026 in Review

Quadrant Capital Group reduced its Recursion Pharmaceuticals (RXRX) stake by 1.2% in Q1 2026, selling an estimated $151 and leaving 3,114 shares worth $9.56K. The position accounts for ﹤0.01% of the portfolio, ranked #2199.

Quadrant Capital Group first reported a position in RXRX in Q3 2024 and has held it in 4 quarters since. The position peaked at $12.9K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Quadrant Capital Group held 3,114 shares of Recursion Pharmaceuticals worth $9.56K as of Q1 2026.
  • Quadrant Capital Group sold 39 Recursion Pharmaceuticals shares in Q1 2026, an estimated $151.
  • Recursion Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2199 holding.
  • Quadrant Capital Group first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Quadrant Capital Group's Recursion Pharmaceuticals position peaked at $12.9K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.